Back to today’s briefing

Story perspectives

Amgen Surpasses Earnings Expectations, Boosts 2025 Guidance

8/6/2025

28 5

Summary

Story summary

Amgen's Q2 earnings reached $6.02 per share, surpassing expectations with $9.18 billion in sales.
Prolia and Enbrel sales fell, but Uplizna surged by 91% to $176 million.
The company increased its 2025 earnings guidance to $20.20-$21.30 per share.
The drug and biotech sector shows mixed earnings results, with several companies reporting this week.

1 of 1

Story summary

Amgen's Q2 earnings reached $6.02 per share, surpassing expectations with $9.18 billion in sales.
Prolia and Enbrel sales fell, but Uplizna surged by 91% to $176 million.
The company increased its 2025 earnings guidance to $20.20-$21.30 per share.
The drug and biotech sector shows mixed earnings results, with several companies reporting this week.